IL264187B - Radioligands for imaging of ido1 enzymatic radioligands for imaging of ido1 enzyme - Google Patents

Radioligands for imaging of ido1 enzymatic radioligands for imaging of ido1 enzyme

Info

Publication number
IL264187B
IL264187B IL264187A IL26418719A IL264187B IL 264187 B IL264187 B IL 264187B IL 264187 A IL264187 A IL 264187A IL 26418719 A IL26418719 A IL 26418719A IL 264187 B IL264187 B IL 264187B
Authority
IL
Israel
Prior art keywords
radioligands
imaging
ido1 enzyme
ido1
enzyme
Prior art date
Application number
IL264187A
Other languages
English (en)
Hebrew (he)
Other versions
IL264187A (en
Inventor
Audris Huang
James Aaron Balog
David J Donnelly
Erin Lee Cole
Richard Charles Burrell
Wesley A Turley
Alban J Allentoff
Michael Arthur Wallace
Mette Skinbjerg
Original Assignee
Bristol Myers Squibb Co
Audris Huang
James Aaron Balog
David J Donnelly
Erin Lee Cole
Richard Charles Burrell
Wesley A Turley
Alban J Allentoff
Michael Arthur Wallace
Mette Skinbjerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Audris Huang, James Aaron Balog, David J Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A Turley, Alban J Allentoff, Michael Arthur Wallace, Mette Skinbjerg filed Critical Bristol Myers Squibb Co
Publication of IL264187A publication Critical patent/IL264187A/en
Publication of IL264187B publication Critical patent/IL264187B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL264187A 2016-07-19 2019-01-10 Radioligands for imaging of ido1 enzymatic radioligands for imaging of ido1 enzyme IL264187B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (2)

Publication Number Publication Date
IL264187A IL264187A (en) 2019-02-28
IL264187B true IL264187B (en) 2021-06-30

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264187A IL264187B (en) 2016-07-19 2019-01-10 Radioligands for imaging of ido1 enzymatic radioligands for imaging of ido1 enzyme

Country Status (12)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503916A1 (en) * 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019006292A1 (en) * 2017-06-30 2019-01-03 Bristol-Myers Squibb Company SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF
JP2021510044A (ja) * 2017-11-21 2021-04-08 オッポ広東移動通信有限公司Guangdong Oppo Mobile Telecommunications Corp., Ltd. 情報伝送方法、ネットワークデバイス及び端末デバイス
WO2019111107A1 (en) * 2017-12-05 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
CN102781316B (zh) * 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
US20220305144A1 (en) 2022-09-29
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
JP6987840B2 (ja) 2022-01-05
MX2019000508A (es) 2019-03-28
JP2019527225A (ja) 2019-09-26
SG11201900336YA (en) 2019-02-27
EP3487516A1 (en) 2019-05-29
CA3031079A1 (en) 2018-01-25
US20190282714A1 (en) 2019-09-19
IL264187A (en) 2019-02-28
CN109475594A (zh) 2019-03-15
AU2017298262A1 (en) 2019-03-07
EA201990198A1 (ru) 2019-06-28
AU2017298262B2 (en) 2024-07-18
BR112019000499A2 (pt) 2019-04-24
EA039877B1 (ru) 2022-03-23
KR102513886B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
IL265369A (en) Antibodies against (mucin 16) muc16
ZA201900373B (en) Anti-tim-3 antibodies
DK3478217T3 (en) Historisk scanningsreference for intraorale scanninger
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201610044D0 (en) Antibodies
EP3250716A4 (en) Microscope-free imaging
GB201802603D0 (en) No details
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201712093D0 (en) Not known
GB201603291D0 (en) Antibodies
GB201712357D0 (en) Spetral imaging
PT3484921T (pt) Anticorpos anti-il-22r
GB2555564B (en) Scatter imaging
PL3491427T3 (pl) Obrazowanie rozproszone
GB201609747D0 (en) Data directed desi-ms imaging
GB201607456D0 (en) Imaging unit
GB201605354D0 (en) Modified enzyme
HK40019095A (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
GB201619982D0 (en) Shields e.g. light-shades
GB201614243D0 (en) Tjti&tjtd
GB201614244D0 (en) Tjti&tjtd

Legal Events

Date Code Title Description
FF Patent granted